Savad Shahram, Mehdipour Parvin, Miryounesi Mohammad, Shirkoohi Reza, Fereidooni Forouzandeh, Mansouri Fatemeh, Modarressi Mohammad Hossein
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Asian Pac J Cancer Prev. 2012;13(3):873-7. doi: 10.7314/apjcp.2012.13.3.873.
MicroRNAs (miRNAs) are short non-coding RNA molecules characterized by their regulatory roles in cancer and gene expression. We analyzed the expression of miR-21, miR-205, and miR-342 in 59 patients with breast cancer. Samples were divided into three different groups according to their immunohistochemistry (IHC) classification: ER-positive and/or PR-positive group (ER+ and/or PR+; group I); HER2-positive group (HER2+; group II); and ER/PR/HER2- negative (ER-/PR-/HER2-; group III) as the triple negative group. The expression levels of the 3 miRNAs were analyzed in the tumor samples and the compared with the normal neighboring dissected tumor (NNDT) samples in all three groups. The expression of miR-21 was similar in all three groups. In patients positive for P53 by IHC, positive for axillary lymph node metastasis and higher tumor stages, it appeared to have significantly elevated. However, significant increase was not found among the 18 fibroadenoma samples. Both miR-205 and miR-342 expressions were significantly down regulated in group III. We conclude that miR-21 does not discriminate between different breast cancer groups. In contrast, miR-205 and miR-342 may be used as potential biomarkers for diagnosis of triple negative breast cancer.
微小RNA（miRNA）是一类短链非编码RNA分子，其在癌症和基因表达中发挥调控作用。我们分析了59例乳腺癌患者中miR-21、miR-205和miR-342的表达情况。根据免疫组织化学（IHC）分类将样本分为三个不同组：雌激素受体阳性和/或孕激素受体阳性组（ER+和/或PR+；第一组）；人表皮生长因子受体2阳性组（HER2+；第二组）；以及雌激素受体/孕激素受体/人表皮生长因子受体2阴性（ER-/PR-/HER2-；第三组）即三阴性组。分析了所有三组肿瘤样本中这3种miRNA的表达水平，并与邻近正常解剖肿瘤（NNDT）样本进行比较。miR-21在所有三组中的表达相似。在免疫组化P53阳性、腋窝淋巴结转移阳性及肿瘤分期较高的患者中，其表达似乎显著升高。然而，在18个纤维腺瘤样本中未发现显著增加。miR-205和miR-342在第三组中的表达均显著下调。我们得出结论，miR-21不能区分不同的乳腺癌组。相比之下，miR-205和miR-342可能用作三阴性乳腺癌诊断的潜在生物标志物。
